TRIM8-driven transcriptomic profile of neural stem cells identified glioma-related nodal genes and pathways by Venuto, Santina et al.
Contents lists available at ScienceDirect
BBA - General Subjects
journal homepage: www.elsevier.com/locate/bbagen
TRIM8-driven transcriptomic proﬁle of neural stem cells identiﬁed glioma-
related nodal genes and pathways
Santina Venutoa,b,1, Stefano Castellanac,1, Maria Montid, Irene Appollonie, Caterina Fusillic,
Carmela Fuscoa, Piero Puccid, Paolo Malatestae,f, Tommaso Mazzac, Giuseppe Merlaa,⁎,2,
Lucia Micalea,⁎,2
a Division of Medical Genetics, Fondazione IRCCS Casa Sollievo della Soﬀerenza, Viale Padre Pio, 71013, San Giovanni Rotondo, Foggia, Italy
b Experimental and Regenerative Medicine, University of Foggia, Via A. Gramsci, 89/91, 71122, Foggia, Italy
c Bioinformatics Unit, Fondazione IRCCS Casa Sollievo della Soﬀerenza, Viale Padre Pio, 71013, San Giovanni Rotondo, Foggia, Italy
d CEINGE Advanced Biotechnology, Department of Chemical Sciences, Federico II University, Via Gaetano Salvatore, 486, 80145, Napoli, Italy
eU.O. Medicina Rigenerativa Ospedale Policlinico San Martino, Largo R. Benzi 10, 16132 Genova, Italy
fDepartment of Experimental Medicine (DiMES), University of Genova, Via Leon Battista Alberti, 2, 16132 Genova, Italy






A B S T R A C T
Background: We recently reported TRIM8, encoding an E3 ubiquitin ligase, as a gene aberrantly expressed in
glioblastoma whose expression suppresses cell growth and induces a signiﬁcant reduction of clonogenic po-
tential in glioblastoma cell lines.
Methods: we provided novel insights on TRIM8 functions by proﬁling the transcriptome of TRIM8-expressing
primary mouse embryonal neural stem cells by RNA-sequencing and bioinformatic analysis. Functional analysis
including luciferase assay, western blot, PCR arrays, Real time quantitative PCR were performed to validate the
transcriptomic data.
Results: Our study identiﬁed enriched pathways related to the neurotransmission and to the central nervous
system (CNS) functions, including axonal guidance, GABA receptor, Ephrin B, synaptic long-term potentiation/
depression, and glutamate receptor signalling pathways. Finally, we provided additional evidence about the
existence of a functional interactive crosstalk between TRIM8 and STAT3.
Conclusions: Our results substantiate the role of TRIM8 in the brain functions through the dysregulation of genes
involved in diﬀerent CNS-related pathways, including JAK-STAT.
General signiﬁcance: This study provides novel insights on the physiological TRIM8 function by proﬁling for the
ﬁrst time the primary Neural Stem Cell over-expressing TRIM8 by using RNA-Sequencing methodology.
1. Introduction
Despite advances in the understanding of the molecular biology of
glioblastoma (GB), this cancer remains incurable. The pathogenesis of
GB is complex due to its highly deregulated genome with opportunistic
deletion of tumour suppressor genes, ampliﬁcation, and/or mutational
hyper-activation of oncogenes, which populate a network of inter-
connected signalling pathways [1,2].
Recently, we reported TRIM8 as a gene aberrantly expressed in
glioblastoma. Ectopic TRIM8 expression suppressed cell growth and
induced a signiﬁcant reduction of clonogenic potential in patient's
primary glioma cell lines [3]. TRIM8 encodes for an E3 ubiquitin ligase
protein [4] that controls multiple physiological functions, including
inﬂammation, cell survival, and diﬀerentiation [5–7]. TRIM8 was re-
ported as a crucial suppressor of the cytokine signalling (SOCS)-1-in-
teracting protein [5] and as a modulator of the molecular switch that
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directs p53 toward the transcriptional activation of cell cycle arrest
genes [6]. Additional studies demonstrated that TRIM8 plays a de-
terminant role in cancer development, including primary larynx squa-
mous cell carcinoma, renal cell carcinoma [6,8].
TRIM8 has been reported as a regulator of stemness and self-re-
newal capabilities of glioma stem cells through STAT3 activation [9].
STAT3 is a member of a family of seven proteins that relays signals from
activated cytokine and growth factor receptors in the plasma membrane
to the nucleus, where they modulate the transcription of responsive
genes involved in the regulation of a variety of critical functions, in-
cluding cell diﬀerentiation, proliferation, apoptosis, angiogenesis, me-
tastasis, and immune responses [10,11]. Multiple lines of evidence
place STAT3 at the centre of development, progression, and main-
tenance of many human tumours, including glioma [12].
Here, we provided novel insights on the physiological functions of
TRIM8 by RNA-Seq proﬁling of primary mouse embryonal neural stem
cells (eNSCs) overexpressing TRIM8. Gene expression analysis identi-
ﬁed several enriched pathways related to neurotransmission and to the
central nervous system (CNS). We reported a number of TRIM8 ex-
pression-related glioma-driving genes, which are aberrantly expressed
and correlate with overall survival of glioma patients. Finally, we
provided additional new data supporting the functional link between
TRIM8 and STAT3 with implications in the development and progres-
sion of glioma.
2. Materials and methods
2.1. Cell lines
Murine embryonic neurospheres were established starting from E14
telencephalic progenitors obtained as described in [13]. Brieﬂy, E14
telencephalic emispheres were dissected from the brain and dissociated
in 1ml of Trypsin/EDTA (Life Technologies) for 15min at 37 °C. DMEM
medium with 10% fetal bovine serum (Thermo Fisher Scientiﬁc) was
then added and cells were mechanically dissociated with a Pasteur
pipette. After centrifugation for 5min at 500 RCF, cells were re-
suspended in neural stem cells medium (DMEM/F12 from Thermo
Fisher Scientiﬁc, 1× B27 supplement from Thermo Fisher Scientiﬁc,
10 ng/ml EGF from Peprotech, 10 ng/ml bFGF from Peprotech) and
seeded in 24 well plates (50,000–150,000 cells/well). After plating,
cells were infected with replication in competent retrovirus expressing
the murine FLAG-tagged Trim8 sequence and a GFP cassette or a con-
trol vector expressing only the GFP cassette. After a short period of
expansion in vitro, infected cells were FACS-sorted to obtain a pure
population of GFP-positive cells that were used for RNA-Seq analysis.
HEK293 and U87MG cell lines were maintained in DMEM with
Glutamax medium supplemented with 10% fetal bovine serum and 1%
antibiotics (Thermo Fisher).
2.2. Retroviral vectors
The murine FLAG-tagged Trim8 sequence was cloned in the
pCAG:GFP MMLV retroviral vector (kindly provided by Dr. M. Goetz,
Institute of Stem Cell Research, Germany), upstream the IRES–GFP
reporter cassette. As control vector we used the same pCAG:GFP vector
expressing only the IRES-GFP cassette. Replication-defective retroviral
supernatants were prepared by transiently transfecting plasmids into
Phoenix packaging cells and harvesting the supernatant after 2 days.
The supernatants were concentrated by centrifugation and stored at
−80 °C before use.
2.3. RNA-Seq library preparation and sequencing
Total RNA was extracted using mini RNase kit reagent (Qiagen) and
treated with DNase-RNase free (Qiagen). RNA integrity was evaluated
by using the Agilent 2100 Bioanalyzer (Agilent Technologies). Next-
generation sequencing experiments were performed by Genomix4Life
S.r.l. (Baronissi, Italy). Indexed libraries were prepared from puriﬁed
RNA with the TruSeq Total Stranded RNA Sample Prep Kit (Illumina)
according to the manufacturer's instructions. Libraries were quantiﬁed
using the Agilent 2100 Bioanalyzer (Agilent Technologies). Index-
tagged samples were equimolar and the overall concentration was
2 nM. The pooled samples were subject to cluster generation and se-
quenced using an Illumina HiSeq 2500 System (Illumina) in a 2×100
paired-end format at a ﬁnal concentration of 8 pmol.
2.4. Pre-processing and mapping reads to the mouse reference genome
RNA-Seq yielded an average number of 68,5 million reads per
sample, ranging from 60 to 86 million reads. Raw data (.fastq ﬁles)
were quality-controlled using the FastQC v0.11.5 software package and
exhibited an average quality score as high as 36 (phred). Reads were
discarded if the average per-base phred values were<20 or trimmed
by Trimmomatic [14] if the phred values of> 5% of nucleotides at the
extremities of the reads were lower than 20. Residual adapter sequences
were removed by cutadapt.> 75% of the paired-end reads were
mapped to the GRCm38 mouse reference genome by TopHat 2. To
summarize the alignments statistics, the resulting BAM ﬁles were ana-
lysed using SAMtools.
2.5. Diﬀerential expression and survival analyses
Uniquely mapped reads were counted and RPKM-normalized. To
assess the cross-sample consistency of the expression proﬁles, the
Pearson's correlation coeﬃcient was calculated for each pairwise
combination of samples. Diﬀerential gene expression was obtained by
one-way ANOVA, as implemented in Partek® Genomics Suite® version
6.6, if Benjamini-Hochberg's FDR-adjusted p-values< .05. Any random
batch eﬀect was mitigated by the Batch Eﬀect Removal® tool of Partek.
Diﬀerentially expressed genes were subjected to Gene Set
Enrichment Analysis (GSEA) by Ingenuity® Pathway Analysis (IPA®,
Qiagen, Summer 2017 Release). The whole procedure of functional
enrichment analysis was based on the prior calculation of the activation
z-scores, by which we inferred the activation states of biological func-
tions and pathways. An enrichment score (Fisher's exact test, p-value),
instead, was calculated to measure the overlap between observed and
predicted deregulated gene sets. We considered p-values< .05, with
positive or negative z-scores indicating predicted activated or inhibited
functions/pathways. Categories of functional annotations were ranked
by a score computed with the weighted sum of the absolute z-scores of
the diseases and functions belonging to the categories. Weights were
calculated as the complement of the inverse of -log p-value (pv), as
reported in [15].
Correlation of expression between functionally relevant genes and
TRIM8 was checked in The Cancer Genome Atlas (TCGA; https://
cancergenome.nih.gov/) cohort of glioma tissues (530 Low Grade
Gliomas and 166 Glioblastomas) through Spearman correlation test.
Considering the high variability of the gene expression proﬁles of these
tumour samples, a minimum correlation value of 0.2 was set.
The Log-Rank test was used to compare the survival distributions of
two samples divided according to the mean expression values of TRIM8
and of other relevant genes. Samples having expression levels greater
than the mean value were assigned to the High group, while samples
with the expression values less or equal to the mean were assigned to
the Low group. All statistical computations were made through R sta-
tistical software (R version 3.3.2).
2.6. PCR arrays validation of RNA-Seq diﬀerential expressed genes
Mouse embryonic neurospheres were infected with a retrovirus
expressing FLAG-Trim8 or with an empty vector. Total RNA was ex-
tracted using mini RNase kit reagent (Qiagen), treated with DNase-
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RNase free (Qiagen), quantiﬁed by Nanodrop (Thermo Fisher Scientiﬁc)
and reverse-transcribed using RT2 First Strand Kit (Qiagen) according to
the manufacturer's instructions. Resulting complementary DNA from
each sample was aliquoted both into mouse Jak-Stat signalling RT2
Proﬁler™ PCR arrays (Qiagen/SABiosciences catalog no. PAMM-039Y,
gene list provided online). Real-time PCRs were performed on an ABI
7900 (Thermo Fisher Scientiﬁc-Applied Biosystems). Data were ana-
lysed by using RT2 Proﬁler PCR Array data analysis software (www.
SABiosciencies.com/pcrarraydataanalysis.php), provided by
SABiosciences.
2.7. Quantitative real time PCR
Total RNA from mouse embryonic neurospheres infected with a
retrovirus expressing FLAG-Trim8 or with an empty vector was reverse
transcribed using the Quantitect Transcription kit (Qiagen), according
to the manufacturer's instructions. Oligos for qPCR were designed using
the Primer express program (Rozen and Skaletsky, 2000) with default
parameters. GAPDH and ACTIN were used as reference genes. The re-
actions were run in triplicate in 10 ul of ﬁnal volume with 10 ng of
sample cDNA, 0.3mM of each primer, and 1XPower SYBR Green PCR
Master Mix (Termo Fisher Scientiﬁc-Applied Biosystems). Reactions
were set up in a 384-well plate format with a Biomeck 2000 (Beckmann
Coulter) and run in an ABI Prism7900HT (Thermo Fisher Scientiﬁc-
Applied Biosystems) with default ampliﬁcation conditions. Raw Ct va-
lues were obtained using SDS 2.3 (Applied Biosystems). Calculations
were carried out by the comparative Ct method as reported in [16].
Signiﬁcance was determined by a two-tailed unpaired t-test for means.
2.8. Dual-luciferase assay
HEK293 and U87MG cells were plated in 12-wells culture dishes at a
density of 4× 104 cells/ml and then co-transfected with a pNanoLuc-
SIE reporter vector (Promega), pGL3-basic FireFly (Promega) and
pDEST-EGFP-STAT3, p3xFLAG-TRIM8 or p3xFLAG-TRIM8 b-box dele-
tion mutant constructs, using Lipofectamine® LTX (Thermo Fisher
Scientiﬁc) according to the manufacturer's instructions. 48 h after
transfection, ﬁreﬂy luciferase activity was monitored using the Dual-
GLO® Luciferase Assay System (Promega) in a Glomax 96 microplate
luminometer and was normalized to the Nano luciferase activity of the
pNanoLuc-SIE vector for each transfected well.
2.9. Co-immunoprecipitation and western blot
HEK293 and U87MG cells were plated in 100mm culture dishes at a
density of 5×105 cells/ml, transfected with the indicated plasmids.
After 48 h, cells were lysed in RIPA buﬀer. Total lysates cells were co-
immunoprecipitated with anti-FLAG (Sigma) or anti-EGFP (Santa Cruz)
using Dynabeads magnetic beads (Thermo Fisher Scientiﬁc) following
manufacturer's instructions. Complexes were analysed by SDS page
electrophoresis and blotted with EGFP, FLAG and STAT3 antibodies, as
reported in [6]. Horseradish peroxidase conjugated anti-mouse (Santa
Cruz) and anti-rabbit (Santa Cruz) antibodies and the ECL chemilumi-
nescence system (GE Healthcare) was used for detection.
2.10. Isolation of nuclear and cytoplasmic extract
HEK293 and U87MG cells were plated in 60mm culture dishes
transfected with the indicated plasmids. After 48 h, cells were harvested
and fractionated. Nuclear and cytoplasmic extraction was prepared
using an NE-PER Nuclear Cytoplasmic Extraction Reagent kit (Pierce)
according to the manufacturer's instruction. Protein concentrations of
cytoplasmic and nuclear extracts were measured using the Pierce
660 nm protein assay (Thermo Fisher Scientiﬁc) with the GloMax
Discover System (Promega). Nuclear and cytoplasmic extracts were
resolved by SDS page electrophoresis and blotted with anti-STAT3
(79D7, Cell Signalling), anti-Phospho-STAT3 (Tyr705, Cell Signalling),
anti-LaminB (Santa Cruz) and anti-αtubulin (Sigma).
ImageJ software was used to quantify band signal intensity. Values
are expressed as fold diﬀerences relative to the endogenous STAT3
protein, set at 1.
2.11. DNA-binding assay
HEK293 cells were plated in 100mm culture dishes at a density of
5× 105 cells/ml, transfected with the indicated plasmids. After 48 h,
cells were lysed in RIPA buﬀer. Protein concentrations of cell lysates
were measured as described above and incubated with the immobilized
STAT3 Consensus Oligonucleotide Sepharose conjugate (Stat3
Consensus oligonucleotide sequence: 5’-GATCCTTCTGGGAATTCCTAG
ATC-3′) (Santa Cruz, sc-2571 AC) in binding buﬀer, according to the
manufacturer's instruction. Samples were centrifuged, washed and
eluted from the beads by using Elution Buﬀer. SDS–PAGE was per-
formed as reported in [17].
2.12. Cell sonication
HEK293 and U87MG cells were plated in 60mm culture dishes and
transfected with FLAG-TRIM8, EGFP-STAT3 and/or empty vectors. 48 h
after transfection, cell pellets were lysed in RIPA buﬀer and than the
suspension was sonicated with a microtip attached to UP50H soniﬁer,
40% amplitude, and constant power 12 times for 60 s, allowing the
suspension to cool on ice for 1min between pulses. After sonication, the
spread of size fragments was checked by running 1 μl of total cell lysate
on a 1% agarose gel.
3. Result and discussion
3.1. TRIM8-related transcriptomic proﬁle
We recently described TRIM8, a nuclear E3 ubiquitin ligase, whose
expression inversely correlates with glioma grade. TRIM8 restoration
suppresses cell growth and induces a signiﬁcant reduction of clonogenic
potential in both U87MG glioblastoma and patients' primary glioma cell
lines [3].
Since E3 ubiquitin ligase proteins regulate carcinogenesis through
the timely control of many cellular processes such as DNA damage re-
sponse, metabolism, transcription, and apoptosis [18–21] we reasoned
that the TRIM8 activity might impact on cell transcriptome patterns,
thereby promoting cancer development and progression. Therefore, we
proﬁled the whole transcriptome of normal embryonic neural stem cells
(eNSC) infected with a retrovirus expressing FLAG-Trim8 by using
RNA-Seq. NSCs display molecular hallmarks of forebrain radial glia and
can be considered as the “bona ﬁde” healthy counterpart of glioma cells
[22]. Moreover, in vitro culture of neural stem cells has proven to be a
valuable experimental approach for exploring molecular processes in
disease models of the central nervous system (CNS) [23].
RNA-Seq revealed 1365 diﬀerentially expressed transcripts of 912
genes (Fig. 1 A). 723 of them (corresponding to 648 RefSeq genes)
diﬀered signiﬁcantly of at least 1.5 folds (192 upregulated transcripts of
178 genes and 531 downregulated transcripts of 470 genes) (Table S1).
80 genes, among all diﬀerentially expressed genes, resulted to sig-
niﬁcantly enrich 18 pathways by IPA analysis (Fig. 1B, Table S2). 53%
of these genes (43 out of 80 genes) are related to cell-morphology, cell
death and survival, with a preponderantly representation of signalling
pathways related to neurotransmission and to CNS, including axonal
guidance, GABA Receptor, ephrin B, synaptic long-term potentiation/
depression, and glutamate receptor (Fig. 1C, Table S2). Four out of ﬁve
CNS-related pathways have in common the M-RAS gene (NM_008624,
p-value= .0060, FC=−1.54), which encodes for a member of the Ras
family of the small GTPases expressed speciﬁcally in brain and heart
(Fig. 1C, Table S2). It functions as a signal transducer in multiple
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processes such as cell growth and diﬀerentiation. The dysregulation of
RAS signalling plays a vital role in the oncogenesis of several cancers,
including glioma [24,25]. Interestingly, MRAS transcriptional activa-
tion is induced by unphosphorylated STAT3 and a strong correlation
between MRAS and STAT3 mRNA has been reported in many cancers
including colon, stomach, ovary, lung, kidney, and rectum [26].
Two out of ﬁve CNS-related pathways, the glutamate receptor and
synaptic long-term potentiation/depression signalling, share GRM8
(NM_008174, p-value= .010, FC=−2.24), GRM1 (NM_001114333, p-
value= .036, FC=8.19), and GRIA4 (NM_0011, p-value= .044,
FC= 1.68) genes. These genes encode for glutamate receptors which
are highly expressed in the mammalian brain and mediate important
functions in cerebellar development, synaptic plasticity, neuroprotec-
tive and neurodegenerative mechanisms (GRM1 and GRM8) [27] and in
(caption on next page)
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fast synaptic excitatory neurotransmission (GRIA4) [28]. Their ex-
pression in the CNS is also regulated by the JAK-STAT signalling
pathway in response to various cytokines, hormones, and growth fac-
tors [29,30].
3.2. Gene set functional enrichment analysis
Gene set enrichment analysis yielded 68 signiﬁcantly represented
biological functions (Fig.1D, Table S3). These line up with the classes of
enriched pathways, which can be ascribed in neurological, neuro-
transmission, transport and cellular organization-related functions.
Among the diﬀerentially expressed genes, VEGFA (NM_001110268,
p-value= .017, FC=−16) is the most pleiotropic gene, since it par-
ticipates to 51 out of 68 biological functions (Table S3) and 4 pathways
out of 18 (Table S2). VEGFA is a member of the PDGF/VEGF growth
factor family that plays multiple roles in the CNS by regulating neu-
ronal migration, angiogenesis, and axonal path ﬁnding [31–33]. VEGFA
is highly expressed in glioma. Glioma cells secrete VEGFA that binds the
VEGFA receptor stimulating the tumour vascular endothelial cell pro-
liferation, migration and tube-like structure formation, and ﬁnally
promotes tumour neovascularization [33,34]. This axis is mediated by a
number of signalling pathways including JAK-STAT [35,36].
3.3. Validation of RNA-Seq data
RNA-Seq analysis revealed a set of genes that resulted diﬀerentially
expressed. For validation we measured the expression of GRIA4, GRM1,
GRM8, MRAS, and VEGFA genes by qPCR analysis on eNSC infected
with a retrovirus expressing FLAG-Trim8, compared to that of control
cells. Accordingly with the RNA-Seq data, we showed an up-regulation
of GRIA4 and GRM1 (FC: 2.37; 2.26, respectively) and a down-regula-
tion of GRM8, MRAS, and VEGFA (FC: 0.5; 0.86; 0.37, respectively)
(Fig. 1E).
Our data analysis has revealed a number of pathways involving the
JAK-STAT regulatory network, one of the most crucial signalling
pathways implicated in the control of CNS functions by modulating the
expression of genes linked to neurogenesis/gliogenesis, hormonal reg-
ulation, synaptic plasticity, and inﬂammation or tumorigenesis in re-
sponse to hormones, growth factors or cytokines [37–39]. Conse-
quently, dysregulation of the JAK-STAT pathway is at the heart of most
brain disorders, including glioma, lesions, ischemia, neurodegenerative
disorders, and epilepsies. [40].
Moreover previous reports linked TRIM8 to the JAK-STAT signalling
pathway. TRIM8 plays a crucial role in controlling STAT3 activation
[9,41,42] and, as many TRIM proteins, TRIM8 expression is induced by
IFN that acts through JAK-STAT signalling pathway inducing the
transcription of a large set of JAK-targeted genes [5].
Pathway analysis revealed perturbation of many genes related to
JAK-STAT. Therefore, we veriﬁed the diﬀerential expression of a set of
genes associated to JAK/STAT using a commercial PCR array. The panel
of mouse genes includes nuclear co-factors, receptors and co-activators
associated with the Stat proteins, Stat-inducible genes, and negative
regulators of the Jak-Stat pathway.
We monitored a global dysregulation of the Jak-Stat pathway in
accordance to RNA-Seq data in eNSC infected with a retrovirus ex-
pressing FLAG-Trim8, compared to control cells (Fig. 1F, S1). For in-
stance, Epor, Jak1, and Smad5 were found signiﬁcantly down-regulated
while Stat3 up-regulated in overexpressing FLAG-Trim8 eNSC, com-
pared to control cells, respectively. Of interest all these four genes are
implicated in glioma. STAT3 is a critical mediator of tumorigenesis,
tumour progression, and suppression of anti-tumour immunity in GB
[43]. The pleiotropic cytokine Erythropoietin, EPO, and its receptor
EPOR were aberrantly expressed in brain tumours and act as crucial
factors in promoting angiogenesis in human gliomas [44]. Finally, JAK1
and SMAD5 were recently found up-regulated in glioma cells [45,46].
In addition, SMAD5 was reported as a target gene of the miR-135
known to be down-regulated in GB cell lines. Forced expression of miR-
135b into glioma stem cells markedly suppressed proliferation, motility
and invasion of glioma cells as well as their stem cell-like phenotype
through targeting SMAD5 [47].
3.4. Correlation of CNS and glioma-related genes expression with TRIM8 in
TCGA cohort
Recently, we evidenced a signiﬁcant increase in the risk of death
and disease progression in WHO grade III gliomas with low TRIM8
expression levels compared to those with high mRNA levels [3].
Our expression data showed that the transcriptional levels of a
number of CNS- and glioma-related genes, such as GRIA4, GRM1,
GRM8, EPOR, SMAD5, MRAS, STAT3, and VEGFA, were signiﬁcantly
perturbed by TRIM8 expression. Therefore, we investigated whether a
correlation may exist between the transcriptional level of TRIM8 and
these brain-related genes in a cohort of 530 Low Grade Glioma (LGG)
and 166 Glioblastoma (GB) tissues from The Cancer Genome Atlas
(TCGA) Research Network. The analysis revealed a signiﬁcant positive
correlation in LGG cohort between the expression of TRIM8 and GRIA4,
while a signiﬁcant negative correlation was found between TRIM8 and
STAT3 and VEGFA. With regard to the GB cohort, TRIM8 expression
positively correlates with GRM1 and STAT3 transcriptional levels
(Fig. 2A).
In order to examine the prognostic value of combined TRIM8 ex-
pression with the transcriptional levels of the above selected genes, we
performed a survival analysis through Log-Rank test in the TCGA cohort
of LGG and GB tissues.
Survival analysis estimated a signiﬁcant decrease of death-risk in
LGG patients with: i) high TRIM8 expression associates to low GRIA4
expression, compared with low TRIM8 and low GRIA4; ii) high TRIM8
with high VEGFA or STAT3, compared with low TRIM8 and high VEGFA
or STAT3. Analysing GB tissues, Kaplan-Meier survival curves high-
lighted that high TRIM8 expression with low STAT3, compared with
high TRIM8 and high STAT3, was co-related to favorable clinical out-
comes in glioma patients (Fig. 2B).
These data suggested that such expression combination might be a
useful supplement to the repertoire of clinicians for predicting survival
time of glioma patients and that the ability to use just one or a handful
of genes to predict outcome could have an impact on therapeutic
Fig. 1. TRIM8-related transcriptomic proﬁle in neural stem cells. (A) Volcano plot of 722 diﬀerentially expressed transcripts (orange-coloured). (B) Forest plot (left)
reporting 18 signiﬁcantly enriched pathways, log(p-value) > 1.3; Stacked bar plot (right) accounting for proportions of upregulated and downregulated genes for
each pathway. (C) EULER diagram representing the number of genes participating to ﬁve signalling pathways related to neurotransmission and to the CNS. (D)
Treemap representing over-represented diseases and biological functions, grouped into processes, as calculated by IPA. Predicted activated processes are coloured in
red, while inhibited processes are coloured in green, according to the inferred zs. Sizes of squares are proportional to -log(p-values). The greater a square, the more
signiﬁcant the enrichment of the function it corresponds to. (E) qPCR analyses were carried out on eNSC infected with a retrovirus expressing FLAG-TRIM8 or FLAG
as control. Data were normalized to the expression of β-actin and L41. Bar represents the average of three replicated experiments± standard errors. (F) The graph
plots the log10 of normalized expression levels of every gene on the array in a control condition (eNSC-expressing only tag, x-axis) versus an experimental condition
(eNSC-expressing FLAG-tagged Trim8, y-axis). Scatter plot: Jak-Stat PCR array, PAMM-039Y. The central line indicates unchanged gene expression. Symbols outside
the delimited area indicate fold-diﬀerences larger than a threshold that we set to 1. The red symbol in the upper-left corner readily identiﬁes up-regulated genes, and
the green symbols in the lower right corner readily identify down-regulated genes. Values were derived by taking the means of fold changes of three biological
replicates per time point.
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Fig. 2. Correlation of CNS and glioma-related genes expression with TRIM8 in TCGA cohort. (A) Spearman correlation between TRIM8 and GRIA4, STAT3, VEGFA,
and GRM1 transcriptional levels. Graphical representation of log-transformed RPKM of 6 genes identiﬁed by RNA-Seq in a cohort of LGG and GB of The Cancer
Genome Atlas Research Network (y axis) and TRIM8 (x axis). Colours represent the density of observations at paired expression values. Higher densities are
represented by red regions and lower densities are in blue, while yellow and green regions have intermediate densities that go from higher to lower, respectively. (B)
Kaplan-Meier curves for Overall Survival according to RNA-Seq FPKM from LGG and GB TCGA data. We performed the Log-Rank test between the combinations of
TRIM8 expression groups and those made by other relevant genes.
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Fig. 3. TRIM8 and STAT3 self-associate (A-B) Whole protein lysates of HEK293 cells transfected with the indicated plasmids, were separated on 10% SDS-PAGE gel
and subjected to immunoblotting with anti-EGFP and anti-FLAG. (C) Schematic representation of STAT3 and TRIM8 structural domains and deletion mutants (SH2:
Src Homology 2; TA: transactivation; R: ring; B1-B2: BBox 1–2; CC: coiled coil; Cterm: C terminal). (D) HEK293 cells were transfected with indicated STAT3 wild type
and mutants together with or without FLAG-tagged TRIM8, immunoprecipitated with anti-FLAG and followed by immunoblot as shown. (* indicates the speciﬁc band
at an higher exposition time). (E) HEK293 cells were transfected with indicated plasmids encoding TRIM8 mutants together with or without EGFP-tagged STAT3. The
immunoprecipitated complexes were analysed by immunoblotting with anti-EGFP and anti-FLAG (low and high exposure). (E) Whole protein lysates of HEK293 cells
transfected with indicated plasmids were processed to obtain nuclear and cytoplasmic fractions, then co-immunoprecipitated with anti-FLAG; the immunocomplexes
were separated on 10% SDS-PAGE gel and subjected to immunoblotting with EGFP, FLAG antibodies; Lamin B and α-tubulin antibodies were used to control nuclear
and cytoplasmic fractions, respectively.
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treatments.
3.5. TRIM8 interacts with STAT3 to promote STAT3 transcriptional activity
directly binding SIE-sequences
Experimental evidences highlighted the existence of a functional
link between TRIM8 and STAT3 in several cellular contexts, including
glioma stem cells [9,41,42]. Consistently we showed here that both
STAT3 and TRIM8 expressions were signiﬁcantly correlated in glioma
tissues and associated to clinical outcomes in glioma patients. There-
fore, based on all these evidences, we investigated the TRIM8-STAT3
loop.
Co-immunoprecipitation experiments using HEK293 and U87MG
cells demonstrated that overexpressed TRIM8 and STAT3 self-associate
(Fig. 3A-B; Fig. S2A, respectively). To delineate the minimal motif re-
gions involved in TRIM8-STAT3 interaction, we used a set of STAT3 and
TRIM8 deletion mutants (Fig. 3C). We found that TRIM8 interacts with
all STAT3 mutants, but with the C-terminal construct expressing only
the transactivation domain, from amino acid 688 to the end of the
STAT3 protein, suggesting that the SH2 domain of STAT3 is required
for the eﬃcient binding of TRIM8. The physical interaction between
TRIM8 and STAT3 persisted also when we used STAT3Y705F, a con-
struct expressing a dominant-negative STAT3 mutant harbouring a
substitution of tyrosine 705 to phenylalanine, which fails to be phos-
phorylated, suggesting that the STAT3 phosphorylation status is
dispensable for TRIM8 interaction (Fig. 3D). When we tested the TRIM8
mutants, we found that all mutants retain the ability to interact with
STAT3 (Fig. 3C, E). Next, we demonstrated that TRIM8 is able to bind
STAT3 in the cytoplasmic cellular compartment as revealed by co-im-
munoprecipitation assays performed on HEK293 and U87MG cell
fractioning (Fig. 3F; Fig. S2B, respectively).
As STAT3 activity is ﬁnely regulated to ensure proper functions,
TRIM8-STAT3 interaction raised the possibility that TRIM8 might
modulate STAT3 transcriptional potential. To explore this, we mon-
itored TRIM8 eﬀect on STAT3 transcriptional activation. We performed
luciferase reporter assays in HEK293 and U87MG cells using a Nano Luc
vector containing the STAT3-inducible element (SIE) (NanoLuc-SIE)
upstream of the luciferase reporter gene. We found a 1.7 and 1.8 sig-
niﬁcant fold increase of luciferase signal in HEK293 cells expressing
exogenous STAT3 or TRIM8, respectively. Interestingly, we detected a
2.7 fold increase of reporter activation in cells co-expressing STAT3 and
TRIM8 (Fig. 4A). Accordingly, we observed a 5.7 fold increase of re-
porter activation in U87MG cells co-expressing STAT3 and TRIM8 (Fig.
S2C). Finally, the inhibition of TRIM8 expression by using speciﬁc
siRNAs reduced the luciferase activity induced by STAT3 (Fig. 4B).
Overall these data suggested that TRIM8 plays a role in the SIE-medi-
ated luciferase transactivation and that its function might be mediated
by endogenous STAT3. These evidences allowed us to hypothesize that
TRIM8 might work together with STAT3 to potentiate the reporter
activation. Next, we investigated the eﬀects of TRIM8 domains in SIE-
Fig. 4. TRIM8 interacts with STAT3 to promote STAT3 transcriptional activity directly binding SIE-sequences. (A) Luciferase assays were performed in HEK293 cells
co-transfected with a pNanoLuc-SIE reporter vector, pGL3-basic FireFly and pDEST-EGFP-STAT3, p3xFLAG-TRIM8 as indicated. (B) Luciferase assays were carried
out in HEK293 cells transfected with control and TRIM8 stealths and then co-transfected with a pNanoLuc-SIE reporter vector, pGL3-basic FireFly, pDEST-EGFP-
STAT3 or pDEST-EGFP-STAT3Y705F, as shown. (C) Luciferase assays were performed in HEK293 cells co-transfected with a pNanoLuc-SIE reporter vector, pGL3-
basic FireFly and indicated plasmids. (A-B-C) top: luciferase activities were normalized to the level of FireFly luciferase. Each bar represents the average of three
independent experiments± standard error (**: p value< .01; *: p value< .05); bottom (A; B) or right (C): total lysates from HEK293 cells used for luciferase assays
in C, D and E were separated on 10% SDS-PAGE gel and subjected to western blot analysis using the indicated antibodies. (D) HEK293 cells were transfected with
pDEST-EGFP-STAT3, p3xFLAG-TRIM8 or empty vector and after 48 h were stimulated with IL-6 (20 ng/ml) for 30min. To measure STAT3 and TRIM8 DNA binding,
cell extracts were treated with the immobilized STAT3 Consensus Oligonucleotide (Santa Cruz)-Sepharose conjugates. The precipitates were subjected to western blot
analysis with FLAG and EGFP antibodies. An aliquot of total cell lysate (TCL) was blotted with the same antibodies. (E) HEK293 cells were transfected with the
indicated plasmids and harvested after 48 h. Cell lysed suspensions in lanes 4–6 were sonicated with a microtip attached to UP50H soniﬁer 12 times for 60 s,
amplitude 40%, cycle 1. Cell lysates were then co-immunoprecipitated with anti-FLAG; the immunocomplexes were separated on 10% SDS-PAGE gel and subjected to
immunoblotting with EGFP and FLAG antibodies.
Fig. 5. Schematic model of the TRIM8 and STAT3
binding to the STAT3-responsive element in the nu-
cleus. The model suggests that in the cytoplasmic
fraction, the ectopic expression of TRIM8 may, on
the one hand strengthen the ability of STAT3 to in-
teract with JAK and on the other promote the de-
gradation of PIAS3 through proteosomal degrada-
tion. These molecular events result in enhanced
STAT3 activation and nuclear translocation. In the
nucleus TRIM8 may contribute to the recruitment of
STAT3 to SIE elements of a repertoire of brain dis-
ease and cancer-related genes.
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binding and reporter activation by performing luciferase assays with a
set of FLAG-tagged TRIM8 deletion mutants (Fig. 3C). We detected that
all TRIM8 mutants partially decreased the luciferase activation both
alone and when co-expressed with STAT3, suggesting the importance of
TRIM8 integrity in the STAT3 activity regulation (Fig. 4C). This activity
is not mediated by the nuclear STAT3Y705 phosphorylation status [48]
as no changes were observed in STAT3Y705 protein level as reported on
(Fig. S2D-E).
Then, we investigated whether the TRIM8 function on STAT3
transactivation is mediated by the TRIM8 binding to SIE. For this
purpose, we monitored the TRIM8 presence at STAT3 consensus se-
quence in cellular extracts obtained from HEK293 cells containing
FLAG-TRIM8 treated with and immobilized to STAT3 Consensus
Oligonucleotide (Santa Cruz)-Sepharose conjugate as described pre-
viously [49]. The precipitates were subjected to western blot analysis.
We detected TRIM8 bound to the STAT3 DNA-consensus in all the
cellular precipitates except for that of negative control (Fig. 4D). These
data supported that TRIM8 binds the STAT3 DNA-consensus.
To assess whether SIE regions participate to TRIM8-STAT3 inter-
action, we performed co-immunoprecipitation experiments after re-
moving DNA from HEK293 total lysates. We found the STAT3-TRIM8
interaction still persisted, suggesting that SIE regions are not essential
for the binding (Fig. 4E; Fig. S2F). All together our data demonstrated a
functional link between TRIM8 and STAT3 in both HEK293 and U87MG
cell lines. Although further detailed work will be required to clarify the
molecular mechanisms and the physiological signiﬁcance of TRIM8-
STAT3 association, we may speculate that in the cytoplasmic fraction,
the ectopic expression of TRIM8 may reinforce the capability of STAT3
to interact with JAK and to promote the proteosomal degradation of
PIAS3 as already suggested elsewhere [41]. Consequently, these mo-
lecular events may accelerate the nuclear import of STAT3, accordingly
to [42]. In the nucleus, TRIM8 may bind STAT3 inducible elements of a
repertoire of brain disease and cancer-related genes probably via nu-
clear factors, resulting in the STAT3 activity enhancement (Fig. 5).
STAT3 is a crucial convergence point of several major oncogenic sig-
nalling pathways, including those of EGFR, PDGFR, c-Met, IL-6R/
gp130, cytoplasmic enzymes in the JAK family, and the Src family of
kinases [50], making STAT3 an attractive molecular therapeutic target
in GB. Thus, the identiﬁcation of new regulators of STAT3 is crucial for
novel therapeutic strategies.
4. Conclusions
The present study provides insights on the physiological functions of
TRIM8 supporting some of the biological processes and the most re-
presentative molecular pathways in which TRIM8 is involved. In par-
ticular, our results imply a role of TRIM8 in the brain functions and in
gliomagenesis through the dysregulation of genes involved in pathways
related to CNS, including the JAK-STAT signalling, further providing
some new clues on how TRIM8 regulates STAT3 transcriptional ac-
tivity.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.bbagen.2018.12.001.
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